Incidence and Factors Associated With Androgenetic Alopecia Among Transgender and Gender-Diverse Patients Treated With Masculinizing Hormone Therapy

Retrospective cohort study (n=988) found androgenetic alopecia increased from 4 (0.4%) to 31 (3.1%) after masculinising hormone therapy (MHT) initiation, with highest incidence in 4th year of MHT and median duration of MHT prior to diagnosis of 2.8 years.

Source:

JAMA Dermatology